Hiroshi Nomoto1, Lina Pei1, Chiara Montemurro1, Madeline Rosenberger1, Allison Furterer2, Giovanni Coppola2, Brian Nadel3, Matteo Pellegrini3, Tatyana Gurlo1, Peter C Butler4, Slavica Tudzarova1,5. 1. Larry L. Hillblom Islet Research Center, David Geffen School of Medicine at UCLA, University of California Los Angeles, 10833 Le Conte Avenue, 33-165 CHS, Los Angeles, CA, 90095-7073, USA. 2. Department of Neurology, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, CA, USA. 3. Molecular Cell and Developmental Biology, College of Life Sciences, University of California Los Angeles, Los Angeles, CA, USA. 4. Larry L. Hillblom Islet Research Center, David Geffen School of Medicine at UCLA, University of California Los Angeles, 10833 Le Conte Avenue, 33-165 CHS, Los Angeles, CA, 90095-7073, USA. pbutler@mednet.ucla.edu. 5. Jonsson Comprehensive Cancer Center, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, CA, USA.
Abstract
AIMS/HYPOTHESIS: The conserved hypoxia inducible factor 1 α (HIF1α) injury-response pro-survival pathway has recently been implicated in early beta cell dysfunction but slow beta cell loss in type 2 diabetes. We hypothesised that the unexplained prolonged prediabetes phase in type 1 diabetes may also be, in part, due to activation of the HIF1α signalling pathway. METHODS: RNA sequencing (RNA-Seq) data from human islets with type 1 diabetes or after cytokine exposure in vitro was evaluated for activation of HIF1α targets. This was corroborated by immunostaining human pancreases from individuals with type 1 diabetes for 6-phosphofructo-2-kinase/fructose-2,6-biphosphatase 3 (PFKFB3), the key effector of HIF1α-mediated metabolic remodelling, and by western blotting of islets and INS-1 832/13 cells exposed to cytokines implicated in type 1 diabetes. RESULTS: HIF1α signalling is activated (p = 4.5 × 10-9) in islets from individuals with type 1 diabetes, and in human islets exposed in vitro to cytokines implicated in type 1 diabetes (p = 1.1 × 10-14). Expression of PFKFB3 is increased fivefold (p < 0.01) in beta cells in type 1 diabetes and in human and rat islets exposed to cytokines that induced increased lactate production. HIF1α attenuates cytokine-induced cell death in beta cells. CONCLUSIONS/ INTERPRETATION: The conserved pro-survival HIF1α-mediated injury-response signalling is activated in beta cells in type 1 diabetes and likely contributes to the relatively slow rate of beta cell loss at the expense of early defective glucose-induced insulin secretion.
AIMS/HYPOTHESIS: The conserved hypoxia inducible factor 1 α (HIF1α) injury-response pro-survival pathway has recently been implicated in early beta cell dysfunction but slow beta cell loss in type 2 diabetes. We hypothesised that the unexplained prolonged prediabetes phase in type 1 diabetes may also be, in part, due to activation of the HIF1α signalling pathway. METHODS: RNA sequencing (RNA-Seq) data from human islets with type 1 diabetes or after cytokine exposure in vitro was evaluated for activation of HIF1α targets. This was corroborated by immunostaining human pancreases from individuals with type 1 diabetes for 6-phosphofructo-2-kinase/fructose-2,6-biphosphatase 3 (PFKFB3), the key effector of HIF1α-mediated metabolic remodelling, and by western blotting of islets and INS-1 832/13 cells exposed to cytokines implicated in type 1 diabetes. RESULTS:HIF1α signalling is activated (p = 4.5 × 10-9) in islets from individuals with type 1 diabetes, and in human islets exposed in vitro to cytokines implicated in type 1 diabetes (p = 1.1 × 10-14). Expression of PFKFB3 is increased fivefold (p < 0.01) in beta cells in type 1 diabetes and in human and rat islets exposed to cytokines that induced increased lactate production. HIF1α attenuates cytokine-induced cell death in beta cells. CONCLUSIONS/ INTERPRETATION: The conserved pro-survival HIF1α-mediated injury-response signalling is activated in beta cells in type 1 diabetes and likely contributes to the relatively slow rate of beta cell loss at the expense of early defective glucose-induced insulin secretion.
Entities:
Keywords:
Cytokines; HIF1α; PFKFB3; Type 1 diabetes
Authors: Mary A Selak; Sean M Armour; Elaine D MacKenzie; Houda Boulahbel; David G Watson; Kyle D Mansfield; Yi Pan; M Celeste Simon; Craig B Thompson; Eyal Gottlieb Journal: Cancer Cell Date: 2005-01 Impact factor: 31.743
Authors: György Szabadkai; Anna Maria Simoni; Mounia Chami; Mariusz R Wieckowski; Richard J Youle; Rosario Rizzuto Journal: Mol Cell Date: 2004-10-08 Impact factor: 17.970
Authors: Thomas Agnew; Michelle Goldsworthy; Carlos Aguilar; Anna Morgan; Michelle Simon; Helen Hilton; Chris Esapa; Yixing Wu; Heather Cater; Liz Bentley; Cheryl Scudamore; Joanna Poulton; Karl J Morten; Kyle Thompson; Langping He; Steve D M Brown; Robert W Taylor; Michael R Bowl; Roger D Cox Journal: Cell Rep Date: 2018-12-18 Impact factor: 9.423
Authors: Zhongying Wang; Tatyana Gurlo; Aleksey V Matveyenko; David Elashoff; Peiyu Wang; Madeline Rosenberger; Jason A Junge; Raymond C Stevens; Kate L White; Scott E Fraser; Peter C Butler Journal: Commun Biol Date: 2021-05-19